Kepivance (Amgen Inc): Full Drug Profile
Kepivance (Amgen Inc) - General Information
Human keratinocyte growth factor (KGF), 140 residues long, expressed in E. coli. First 23 residues removed to improve stability.
Pharmacology of Kepivance (Amgen Inc)
Used in the prevention or treatment of oral mucoscitis (mouth ulcers arising from chemotherapy), Kepivance binds to the human keratinocyte growth factor (KGF) receptor on buccal cell surfaces. Kepivance acts as both a cell growth and survival factor by stimulating epithelial cell proliferation, differentiation, and migration around the tongue and mouth. The KGF receptor is found on many tissues particularly around the tongue, esophagus, salivary gland and other gastro-intestinal tract organs.
Additional information about Kepivance (Amgen Inc)
Kepivance (Amgen Inc) Indication: For treatment of mucositis (mouth sores) Mechanism Of Action: Kepivance binds to the human keratinocyte growth factor (KGF) receptor found on buccal cell surfaces. The binding activates a Ras-MapK (Map kinase) signaling pathway which leads to the transcriptional activation of many proteins important for cell growth and survival. Drug Interactions: Not Available Food Interactions: Not Available Generic Name: Palifermin Synonyms: FGF-7; Fibroblast growth factor- 7; HBGF-7; KGF; Keratinocyte growth factor precursor Drug Category: Antimucositis Agents Drug Type: Biotech; Approved Other Brand Names containing Palifermin: Kepivance (Amgen Inc); Absorption: Not Available Toxicity (Overdose): Not Available Protein Binding: Not Available Biotransformation: Not Available Half Life: Not Available Dosage Forms of Kepivance (Amgen Inc): Powder, for solution Intravenous Chemical IUPAC Name: Human keratinocyte growth factor Chemical Formula: C721H1142N202O204S9 Palifermin on Wikipedia: https://en.wikipedia.org/wiki/Palifermin Organisms Affected: Humans and other mammals